The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Imatinib mesylate in thymic epithelial malignancies.
C. Buonerba
No relevant relationships to disclose
M. Marino
No relevant relationships to disclose
S. Sioletic
No relevant relationships to disclose
S. Conti
No relevant relationships to disclose
L. Petillo
No relevant relationships to disclose
P. Federico
No relevant relationships to disclose
V. Damiano
No relevant relationships to disclose
G. Merola
No relevant relationships to disclose
A. Evoli
No relevant relationships to disclose
M. Lalle
No relevant relationships to disclose
A. Ceribelli
No relevant relationships to disclose
M. Milella
No relevant relationships to disclose
G. Palmieri
No relevant relationships to disclose